- Home
- NRSN vs BIAF Comparison
NRSN vs BIAF Comparison
Compare NRSN & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- BIAF
- Stock Information
- Founded
- NRSN 2017
- BIAF 2014
- Country
- NRSN Israel
- BIAF United States
- Employees
- NRSN N/A
- BIAF N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NRSN Health Care
- BIAF Health Care
- Exchange
- NRSN Nasdaq
- BIAF Nasdaq
- Market Cap
- NRSN 26.3M
- BIAF 21.4M
- IPO Year
- NRSN 2021
- BIAF 2022
- Fundamental
- Price
- NRSN $1.31
- BIAF $1.25
- Analyst Decision
- NRSN
- BIAF Strong Buy
- Analyst Count
- NRSN 0
- BIAF 1
- Target Price
- NRSN N/A
- BIAF $6.00
- AVG Volume (30 Days)
- NRSN 181.1K
- BIAF 220.8K
- Earning Date
- NRSN 11-26-2024
- BIAF 11-14-2024
- Dividend Yield
- NRSN N/A
- BIAF N/A
- EPS Growth
- NRSN N/A
- BIAF N/A
- EPS
- NRSN N/A
- BIAF N/A
- Revenue
- NRSN N/A
- BIAF $7,315,883.00
- Revenue This Year
- NRSN N/A
- BIAF $302.41
- Revenue Next Year
- NRSN N/A
- BIAF $15.00
- P/E Ratio
- NRSN N/A
- BIAF N/A
- Revenue Growth
- NRSN N/A
- BIAF 30185.99
- 52 Week Low
- NRSN $0.47
- BIAF $1.21
- 52 Week High
- NRSN $2.33
- BIAF $3.62
- Technical
- Relative Strength Index (RSI)
- NRSN 61.44
- BIAF 34.94
- Support Level
- NRSN $1.23
- BIAF $1.30
- Resistance Level
- NRSN $1.34
- BIAF $1.37
- Average True Range (ATR)
- NRSN 0.10
- BIAF 0.07
- MACD
- NRSN 0.01
- BIAF -0.00
- Stochastic Oscillator
- NRSN 75.00
- BIAF 0.00
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.